Summary & Overview
CPT 0660T: Intraocular Implant Drug Delivery to Anterior Segment
CPT code 0660T describes the surgical insertion of an intraocular implant that delivers a medication at a controlled rate into the anterior segment of the eye, commonly used to treat glaucoma and similar anterior‑segment conditions. As an emerging procedural code for device‑mediated drug delivery, it matters nationally for ophthalmology practice patterns, device adoption, and payer coverage policy given potential impacts on care pathways and long‑term medication management.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the procedure, typical sites of service (ambulatory surgery centers and hospital outpatient departments), and the kinds of benchmarks and policy topics that influence adoption and reimbursement—such as coding application, coverage variability among major payers, and implications for procedure coding and billing workflows.
The publication also summarizes policy updates, common billing modifiers used with surgical procedures, and points of attention for coding accuracy and documentation. Data not available in the input will be identified where relevant. This national summary is intended for coding professionals, practice managers, and clinical leaders seeking a concise reference on CPT code 0660T and its role in ophthalmic procedural care.
Billing Code Overview
CPT code 0660T represents the insertion of an implanted, controlled‑release drug delivery device into the anterior segment of the eye to treat conditions such as glaucoma. The procedure involves placing an intraocular implant designed to deliver medication at a controlled rate to the front‑most region of the eye.
-
Service type: Intraocular implant drug delivery procedure
-
Typical site of service: Ambulatory surgery center or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A 72-year-old patient with progressive primary open-angle glaucoma uncontrolled on maximal topical therapy presents for evaluation. After clinical assessment including slit-lamp exam, gonioscopy, intraocular pressure (IOP) measurement, and optic nerve imaging, the ophthalmologist recommends placement of an intraocular, sustained-release anterior segment drug implant to deliver medication directly to the eye over an extended period to reduce IOP and improve adherence compared with topical drops. The procedure is performed in an outpatient ambulatory surgery center or hospital outpatient department under monitored anesthesia care or local/regional anesthesia. The typical workflow includes preoperative counseling and consent, topical antisepsis and sterile draping, insertion of the implant into the anterior chamber via a small corneal or limbal incision with device delivery system, confirmation of implant position, minimal intraoperative irrigation/aspiration as needed, wound closure if required, and immediate postoperative assessment. Postoperative care includes topical antibiotics and anti-inflammatory medications, IOP checks, and follow-up visits to monitor implant position, IOP response, and for potential complications such as corneal endothelial changes, anterior chamber inflammation, hyphema, or wound leak.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased Procedural Service | Use when work required to perform the implant is substantially greater than typical. |